reports
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimeti...
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA – End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks – NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-...
Cellectar Biosciences Announces Strategic Supply Agreement with Ioneti...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a multi-year supply agreement with Ionetix Corporation, a leading cyclotron technology inno...
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering’s addition will become effective prior to market open on Monday, December 22, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classifie...
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Con...
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Off...
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and...
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP) Initiated Phase 1b Study of CLR 125 for TNBC Received Rare Pediatric Drug Designation for Iopofosine I 131 in Inoperable Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., ...
Immuneering Reports Third Quarter 2025 Financial Results and Provides ...
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates - Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with Sanofi - - Cash runway extended into 2029, including through topline readout of planned Phase 3 trial of atebimetinib + mGnP in first-line pancreatic cancer - - Granted U.S. composition of matter patent for atebimetinib that is expected to provide exclusivity into 2042 - - New...
Cellectar Biosciences to Report Third Quarter Financial Results and Ho...
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2025, and provide a corporate update on November 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, November...
Immuneering to Report Third Quarter 2025 Financial Results and Provide...
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 - New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET - NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that the company will report third quarter 2025 financ...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival FLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today...
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
PNFP PINNACLE FINANCIAL PARTNERS INC.
FDS FACTSET RESEARCH SYSTEMS INC.
DENN DENNY'S CORPORATION
CNS COHEN & STEERS INC.
CMC COMMERCIAL METALS COMPANY
CAPL CROSSAMERICA PARTNERS LP
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
ATRO ASTRONICS CORPORATION
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
FBK FB FINANCIAL CORPORATION
GRF EAGLE CAPITAL GROWTH FUND INC
GWRS GLOBAL WATER RESOURCES
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
STRO CPS TECHNOLOGIES
GRX SUTRO BIOPHARMA
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
PCB PENNANT GROUP
WWR PACIFIC CITY FINANCIAL CORP
ACET WESTWATER RESOURCES
CGEM ADICET BIO INC
SMMT CULLINAN ONCOLOGY INC
INTA SUMMIT THERAPEUTICS INC
IMRX INTAPP INC
REFI IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
EP VIVANI MEDICAL INC
SOC EMPIRE PETROLEUM CORP
LAW SABLE OFFSHORE CORP
HYMC CS DISCO INC
NUGN HYCROFT MINING HOLDING CORPORATION
LIVENTO GROUP
INC.
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CAPL CROSSAMERICA PARTNERS LP
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
GWRS GLOBAL WATER RESOURCES
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
FUND CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
STRO INC.
SAVA FIRST GUARANTY BANCSHARES
DX SUTRO BIOPHARMA
PNTG CASSAVA SCIENCES
PCB DYNEX CAPITAL INC.
WWR PENNANT GROUP
ACET PACIFIC CITY FINANCIAL CORP
ALTM WESTWATER RESOURCES
CGEM ADICET BIO INC
OPEN ALTUS MIDSTREAM COMPANY (A)
GGZ CULLINAN ONCOLOGY INC
IMRX OPENDOOR TECHNOLOGIES INC.
REFI GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
UAMY PEPGEN INC
SOC VIVANI MEDICAL INC
LAW U S ANTIMONY CORP
MRAI SABLE OFFSHORE CORP
HYMC CS DISCO INC
SABS MARPAI
INC.
HYCROFT MINING HOLDING CORPORATION
BIG CYPRESS ACQUISITION CORP.
Cellectar Biosciences Presented Promising Preclinical Data in Poster P...
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that ...
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
GWRS INC.
AROC GLOBAL WATER RESOURCES
ZIVO ARCHROCK INC.
CPSH ZIVO BIOSCIENCE
FUND INC.
ARVN CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
BCDA INC.
SAVA ARVINAS HOLDING
DX FIRST GUARANTY BANCSHARES
AOUT BIOCARDIA
ACET CASSAVA SCIENCES
ALTM DYNEX CAPITAL INC.
CGEM AMERICAN OUTDOOR BRANDS
OPEN INC.
GGZ ADICET BIO INC
IMRX ALTUS MIDSTREAM COMPANY (A)
ABSI CULLINAN ONCOLOGY INC
PEPG OPENDOOR TECHNOLOGIES INC.
MRVL GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
UAMY IMMUNEERING CORP
PRAX ABSCI CORP
LAW PEPGEN INC
MRAI MARVEL BIOSCIENCES CORP
JSPR U S ANTIMONY CORP
BDSX PRAXIS PRECISION MEDICINES INC
SABS CS DISCO INC
MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Milli...
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the company and several institutional investors to exercise certain existing warrants (the “Existing Warrants”) for gross proceeds to the company of approximately $5.8 million prior to deducting placement agent fees and estimated offering expe...
Cellectar Biosciences Announces European Medicines Agency (EMA) Confir...
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected in Early 2026 Potential 2027 European Approval and Commercial Launch of Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM FLORHAM PARK, N.J., O...
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
SMRT INC.
MBIN SMARTSPACE SOFTWARE
AROC MERCHANTS BANCORP
FUND ARCHROCK INC.
ARVN ROYCE FOCUS TRUST
FGBI INC.
BCDA ARVINAS HOLDING
UUU FIRST GUARANTY BANCSHARES
SAVA BIOCARDIA
DX UNIVERSAL SECURITY INSTRUMENTS INC.
AOUT CASSAVA SCIENCES
ALXO DYNEX CAPITAL INC.
ALTM AMERICAN OUTDOOR BRANDS
AMR INC.
OPEN ALX ONCOLOGY HOLDINGS
GGZ ALTUS MIDSTREAM COMPANY (A)
IMRX ALPHA METALLURGICAL RESOURCES INC
ABSI OPENDOOR TECHNOLOGIES INC.
RYAN GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
MRVL ABSCI CORP
BUKS RYAN SPECIALTY GROUP HLDGS INC
OBLG PEPGEN INC
VANI MARVEL BIOSCIENCES CORP
UAMY BUTLER NATIONAL CORP
PRAX OBLONG INC
NCDL VIVANI MEDICAL INC
NEXT U S ANTIMONY CORP
MRAI PRAXIS PRECISION MEDICINES INC
JSPR NUVEEN CHURCHILL DIRECT LENDING CORP
BDSX NEXTSOURCE MATERIALS INC.
SABS MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
Cellectar Biosciences Presented Compelling Data in Oral Session and Pa...
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival FLORHAM PARK, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the trea...
Immuneering to Discuss Recently Announced Overall Survival Data from P...
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.